MOLTO: Multi-maintenance Olaparib after Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this clinical trial if you have:
- a recurrence of high grade serous or endometrioid ovarian cancer, fallopian tube or primary peritoneal cancer
- at least one area of cancer that can be measured on a CT scan
- a mutation in the BRCA1 or BRCA2 gene
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
Olaparib is a type of targeted treatment known as a PARP inhibitor. It blocks an enzyme called PARP, which helps damaged cancer cells to repair themselves. When PARP doesn't work the cancer cells won't be able to repair themselves and will die. Because of this, drugs such as olaparib are known to lengthen the amount of time between receiving chemotherapy and the cancer coming back (recurring).
This study is looking at whether it's safe to give women whose ovarian cancer has come back a second course of olaparib. The researchers also want to find out how well olaparib works at stopping the cancer from coming back.
The drugs involved in this trial are:
- Olaparib – a PARP inhibitor. This is a tablet taken twice a day. How long women take this for depends on whether they have taken olaparib before.
- Cediranib – a VEGF inhibitor. This is a tablet taken once a day. Cediranib will be given to women to take at the same time as olaparib when their previous treatment with olaparib finished less than six months ago.
